Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029
Description
Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information’s latest report, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.
Market Drivers & Opportunities
mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.
With leading companies such as Abbott, Cepheid, bioMérieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:
This report offers detailed segmentation of the mPOC market, including:
Market Drivers & Opportunities
mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.
With leading companies such as Abbott, Cepheid, bioMérieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:
- What is the size and projected growth of the mPOC market?
- Which companies are leading the market, and how are they positioned?
- How is mPOC impacting traditional laboratory-based molecular testing?
- What regions and disease segments present the greatest opportunities?
This report offers detailed segmentation of the mPOC market, including:
- Market Sizing & Forecasts (2024-2029) – Revenue projections by technology, region, and disease area.
- Competitive Analysis – Market share breakdowns and insights into leading companies.
- Geographic Trends – Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
- Technology & Regulatory Landscape – Overview of CLIA-waived and moderate-complexity molecular platforms.
Scope
Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029 provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.
This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between "true" molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market's growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.
A Decade of mPOC Research Expertise
Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, offers critical insights to help you navigate and capitalize on this fast-growing segment.
Table of Contents
140 Pages
- Molecular Point-of-Care Market, 2024-2029 ($ million)
- Near Patient Molecular Systems Market, 2024-2029 ($ million)
- Where is Molecular Point-of-Care in 2025?
- Molecular Point-of-Care Market Analysis
- Current Trends
- Trends
- Scope and Methodology
- COVID-19 and Molecular POC
- Regulatory Developments
- Consortia, Funding, Prizes
- Deals
- Advantages and Disadvantages of Molecular Point-of-Care
- Justification: The Sensitivity/Specificity Argument
- New Systems and Menu Expansion
- Deals, Investment in mPOC Systems
- China as a POC Market
- Common Tests and Analytes in POC Diagnostics
- Component Technologies of Molecular Point-of-Care Diagnostics
- Applications and Potential Applications for Molecular Point-of-Care
- European Device Regulations
- Molecular Point-of-Care Market Analysis
- "Near Patient Molecular" Market
- Abbott Laboratories
- Aidian Oy
- Akonni Biosystems
- binx health, inc.
- Biocartis NV
- bioMérieux SA
- Cepheid (Danaher)
- Credo Diagnostics Biomedical Pte. Ltd.
- Curetis NV (OpGen)
- DiaSorin S.p.A
- GenMark Diagnostics (Roche)
- Greiner Bio-One GmbH
- Lucira Health (Pfizer)
- Meridian Bioscience, Inc. (SD Biosensor)
- Mesa Biotech, Inc. (Thermo)
- QIAGEN NV
- QuantuMDx Group
- QuidelOrtho Corporation
- Roche
- Sekisui Diagnostics LLC
- T2 Biosystems
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
